Gene therapy developer Krystal has received $7m in funding from Sun Pharmaceutical Industries, in a deal that values the startup at roughly $44m.
Pharmaceutical company Sun Pharmaceutical Industries is set to pay $7m for a 15.9% stake in US-based rare and orphan disease therapy startup Krystal Biotech, VCCircle has reported citing a stock market filing.
Founded in March 2017, Krystal is developing gene therapies for rare and orphan diseases. India-based Sun Pharma has not revealed further details concerning its investment or whether the funding was provided in connection with any kind of strategic partnership.